Cedars-Sinai Medical Center |
Dhruv Sareen |
Manufacturing Network Grant |
A comprehensive biomanufacturing center solving bottlenecks in cell and gene therapy manufacturing to accelerate new therapies for California patients |
$2,000,000 |
Stanford University |
Steven Feldman |
Manufacturing Network Grant |
Laboratory for Cell and Gene Medicine: A partner in the California Cell and Gene Therapy Manufacturing Network |
$2,000,000 |
University of California, San Francisco |
Brian Shy |
Manufacturing Network Grant |
Open Manufacturing Network for Cell and Gene Therapies |
$1,999,993 |
University of California, Los Angeles |
Dawn Ward |
Manufacturing Network Grant |
Enhancing California’s Manufacturing of Leading-Edge Cell & Gene Therapies |
$2,000,000 |
City of Hope, Beckman Research Institute |
Taby Ahsan |
Manufacturing Network Grant |
Scalable Expansion for Stem Cell-derived Therapies |
$1,998,174 |
Eureka Therapeutics, Inc. |
Pei Wang |
Clinical Trial Stage Projects |
Autologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer |
$10,600,072 |
University of California, Los Angeles |
Steven Schwartz |
Late Stage Preclinical Projects |
Clinical Translation of Autologous Regenerative Pluripotent Stem Cell Therapy for Blindness |
$6,000,000 |
University of California, Irvine |
Kyriacos Athanasiou |
Late Stage Preclinical Projects |
Treatment of the TMJ disc complex |
$6,000,000 |
Stanford University |
Matthew Porteus |
Clinical Trial Stage Projects |
Reduced intensity conditioning with JSP191 prior to TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic stem cell transplant for Fanconi Anemia patients |
$10,642,420 |
Combangio, Inc. |
R. Brazzell |
Clinical Trial Stage Projects |
Phase 2b Clinical Study of KPI-012 Topical Ophthalmic Human Mesenchymal Stem Cell Secretome for the Treatment of Persistent Corneal Epithelial Defect |
$15,000,000 |
VxBiosciences inc. |
Leor Weinberger |
Therapeutic Translational Research Projects |
Escape-Resistant Oligonucleotide Therapy (ONT) for Cytomegalovirus (CMV) Disease in Hematopoietic Stem-Cell and Solid-Organ Transplant Patients |
$3,977,180 |
Stanford University |
Walter Park |
Therapeutic Translational Research Projects |
Enhanced Autologous Pancreatic Islet Transplantation and Survival for Diabetes Mellitus Therapy |
$6,056,713 |
University of Southern California |
Rongfu Wang |
Therapeutic Translational Research Projects |
Novel T cell receptor-STEM T cell immunotherapy in lung cancer |
$5,689,540 |
Rejuvenation Technologies, Inc. |
John Ramunas |
Therapeutic Translational Research Projects |
Telomerase mRNA for short telomere related pulmonary fibrosis |
$3,984,942 |
University of California, Los Angeles |
Scott Kitchen |
Therapeutic Translational Research Projects |
Hematopoietic Stem/Progenitor Cell-Based Chimeric Antigen Receptor Gene Therapy for HIV Infection |
$6,140,723 |
University of California, Los Angeles |
Sophie Deng |
Therapeutic Translational Research Projects |
Extracellular Vesicle-Based Therapy for Corneal Scars |
$5,779,276 |
BrainXell Therapeutics |
Emmanuel Baetge |
Therapeutic Translational Research Projects |
Development of Autologous Cell Replacement Therapy for Parkinson’s Disease: Path to Personalized Treatment |
$3,841,110 |
ImmunoVec |
Luke Riggan |
Therapeutic Translational Research Projects |
Hematopoietic Stem Cell Gene Therapy for Wiskott Aldrich Syndrome |
$3,999,899 |
University of California, Los Angeles |
Anthony Aldave |
Therapeutic Translational Research Projects |
AAV Gene Therapy for Treating Congenital Hereditary Endothelial Dystrophy associated with Biallelic SLC4A11 Mutations |
$4,338,166 |
City of Hope, Beckman Research Institute |
Michael Caligiuri |
Therapeutic Translational Research Projects |
Targeting multiple myeloma with BCMA-CAR NK cells expressing a GPRC5D-NKG2D bispecific antibody |
$6,036,001 |
Cedars-Sinai Medical Center |
Wafa Tawackoli |
Conference II |
1st Annual Greater Los Angeles Regenerative Medicine Summit |
$35,100 |
Lineage Cell Therapeutics, Inc. |
Ioana Hone |
Conference II |
1st Annual Spinal Cord Injury Investor Symposium (SCIIS) |
$50,000 |
University of California, San Francisco |
Jeffrey Lotz |
Conference II |
2023 Center for Dental, Oral, & Craniofacial Tissue & Organ Regeneration (C-DOCTOR) Annual Spring Conference |
$30,250 |
University of Southern California |
Qifa Zhou |
Conference II |
The 15th International Conference on the Ultrasound Engineering and Biomedical Applications |
$25,000 |
University of California, San Francisco |
Elizabeth Crouch |
Foundation - Discovery Stage Research Projects |
Harnessing vascular stem cells to grow and protect the human brain |
$1,391,998 |
University of California, Los Angeles |
Gay Crooks |
Foundation - Discovery Stage Research Projects |
Engineering pluripotent stem cells for universally available, off-the-shelf T cell therapies |
$1,352,753 |
University of California, San Diego |
Alon Goren |
Foundation - Discovery Stage Research Projects |
Establishment of a novel approach to systematically study the dynamic organization of protein complexes in stem cells |
$1,515,601 |
Scripps Research Institute |
Xin Jin |
Foundation - Discovery Stage Research Projects |
Functional genomics to study cellular convergence across ASD risk genes in neurodevelopment |
$1,575,001 |
University of California, San Francisco |
Tomasz Nowakowski |
Foundation - Discovery Stage Research Projects |
Identifying roadblocks to neural stem cell transplantation into human tissues. |
$1,551,394 |
University of California, Irvine |
Brian Cummings |
Foundation - Discovery Stage Research Projects |
Mapping the spatial and temporal responses of hESC-derived microglia to repeat mild closed head injury to identify therapeutic targets and mechanisms |
$1,555,140 |
University of California, Irvine |
Albert La Spada |
Foundation - Discovery Stage Research Projects |
Role of ataxin-3 polyadenylation site selection in ALS neuron toxicity and disease pathogenesis |
$1,514,416 |
University of California, San Francisco |
Deepak Lamba |
Foundation - Discovery Stage Research Projects |
Modeling Retinitis Pigmentosa using patient-derived human iPSC organoids |
$1,612,617 |
University of California, Los Angeles |
Brigitte Gomperts |
Foundation - Discovery Stage Research Projects |
Overcoming barriers for airway stem cell gene therapy for Cystic Fibrosis |
$1,472,858 |
University of California, San Francisco |
TIEN PENG |
Foundation - Discovery Stage Research Projects |
Ex vivo fate mapping of human lung stem cell plasticity in fibrotic disease |
$1,625,998 |
University of California, Los Angeles |
Kathrin Plath |
Foundation - Discovery Stage Research Projects |
Characterization and applications of human blastoids for understanding early human embryogenesis |
$1,402,137 |
University of California, Santa Cruz |
Maximilian Haeussler |
Foundation - Discovery Stage Research Projects |
An interactive data resource for hypothesis testing in stem cell single-cell gene expression and validation of the results with brain organoids |
$1,160,126 |
University of California, Los Angeles |
William Lowry |
Foundation - Discovery Stage Research Projects |
Defining the source of dysfunction in monogenic Intellectual Disability Syndrome neurons |
$1,500,337 |
University of California, San Francisco |
Faranak Fattahi |
Foundation - Discovery Stage Research Projects |
hPSC-derived enteric ganglioids for cell therapy in gastrointestinal motility disorders |
$1,589,307 |
Cedars-Sinai Medical Center |
Dmitriy Sheyn |
Foundation - Discovery Stage Research Projects |
The role of WNT and BMP signaling pathways in iPSC to iTenocyte step-wise differentiation for tendon repair |
$1,516,563 |
University of California, San Francisco |
Yin Shen |
Foundation - Discovery Stage Research Projects |
Understanding Chemotherapy-Induced Peripheral Neuropathy Mechanisms using CRISPRi and Chemical Screens in Human iPSC-Derived Sensory Neurons |
$1,621,913 |
University of California, Santa Cruz |
Camilla Forsberg |
Foundation - Discovery Stage Research Projects |
Determining how age-specific heterogeneity of human hematopoietic stem cells and megakaryocyte progenitors contribute to thrombotic disease upon aging |
$1,536,000 |
Cedars-Sinai Medical Center |
Wafa Tawackoli |
Conference - Manage The SPARK Annual Meeting |
2023 CIRM SPARK Research Conference |
$100,000 |
Rampart Bioscience |
Jeffrey Bartlett |
Late Stage Preclinical Projects |
Ex vivo Engineering of Autologous Hematopoietic Stem Cells for the Treatment of Hypophosphatasia |
$3,999,980 |
Genascence Corporation |
Thomas Chalberg |
Clinical Trial Stage Projects |
A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study of GNSC-001 Evaluating Safety, Pharmacodynamics, and Biomarkers in Knee OA |
$11,637,194 |
Stanford University |
Joseph Wu |
Conference II |
Stanford Drug Discovery Symposium 2023 |
$50,000 |
University of California, Berkeley |
John Dueber |
Conference II |
BIC 2023 - 23rd Annual UC Systemwide Bioengineering Symposium |
$50,000 |
Stanford University |
Everett Meyer |
Conference II |
Cellular Immune Tolerance Symposium |
$32,751 |
University of California, Davis |
Aijun Wang |
Quest - Discovery Stage Research Projects |
In Utero Treatment of Duchenne Muscular Dystrophy with Non-viral Gene Editing |
$2,035,544 |
University of California, Berkeley |
Fyodor Urnov |
Quest - Discovery Stage Research Projects |
A Treatment for Artemis-deficient Severe Combined Immunodeficiency using Non-Viral CRISPR-driven Safe Harbor Transgenesis in Hematopoietic Stem Cells |
$1,809,372 |
Greenstone Biosciences, Inc. |
Paul Pang |
Quest - Discovery Stage Research Projects |
Drug Discovery for Duchenne Muscular Dystrophy Using Patient-Derived Human iPSCs |
$675,000 |
University of California, Los Angeles |
Richard Pietras |
Quest - Discovery Stage Research Projects |
Reversal of dysregulated myelopoiesis in breast cancers and cancer stem cells to boost antitumor immunotherapy |
$2,327,680 |
University of California, Los Angeles |
Song Li |
Quest - Discovery Stage Research Projects |
Vax-CT to promote formation of cancer-specific T memory stem cell for personalized cancer immunotherapy |
$2,267,714 |
Ossium Health |
Brian Johnstone |
Late Stage Preclinical Projects |
Development of OSSM-007, cryopreserved interferon-gamma primed allogeneic MSCs, for treatment of steroid refractory acute graft versus host disease |
$3,457,858 |
Gladstone Institutes, J. David |
Lyandysha Zholudeva |
Quest - Discovery Stage Research Projects |
Excitatory spinal interneurons from human pluripotent stem cells to treat spinal cord injury |
$2,942,198 |
Ryne Bio |
Howard Federoff |
Late Stage Preclinical Projects |
Allogeneic iPSC derived Dopaminergic Drug Product for Parkinson's disease |
$4,000,000 |
City of Hope, Beckman Research Institute |
Jianhua Yu |
Quest - Discovery Stage Research Projects |
Reprogramming Somatic Cells into iPSCs Engineered with an Anti-PSCA CAR to Develop Allogeneic Off-the-Shelf Cell Therapy to Treat Pancreatic Cancer |
$2,263,500 |
Immusoft Corporation |
Robert Hayes |
Clinical Trial Stage Projects |
A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1 |
$8,000,000 |
BrainXell Therapeutics |
Matthew Goodus |
Quest - Discovery Stage Research Projects |
Autologous stem cell-derived interneuron cell therapy for spinal cord injury (SCI) |
$2,025,000 |
University of California, Berkeley |
Kevin Healy |
Quest - Discovery Stage Research Projects |
Novel Lipid Nanoparticles for Enhancing eNOS Synthesis for Cardioprotection Post Myocardial Infarction |
$2,060,248 |
Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center |
Michelina Iacovino |
Quest - Discovery Stage Research Projects |
A Novel Therapy for Sanfilippo B |
$2,297,884 |
Cedars-Sinai Medical Center |
Dmitriy Sheyn |
Quest - Discovery Stage Research Projects |
Microgel encapsulated iPSC-derived notochordal cells to treat intervertebral disc degeneration and low back pain |
$2,020,166 |
Scripps Health |
Darryl D’Lima |
Quest - Discovery Stage Research Projects |
Pluripotent Stem Cells for Tendon Tissue Engineering |
$2,734,163 |
University of California, Los Angeles |
Frank Pajonk |
Quest - Discovery Stage Research Projects |
Development of novel small molecules against cancer stem cells in solid cancers |
$2,340,000 |
University of California, Los Angeles |
Gerald Lipshutz |
Quest - Discovery Stage Research Projects |
Gene Therapy for SLC6A8 Creatine Transporter Disorder |
$2,296,920 |
Rubedo Life Sciences Inc. |
Marco Quarta |
Quest - Discovery Stage Research Projects |
Pharmacological regenerative treatment of idiopathic pulmonary fibrosis targeting the senescent niche of lung progenitor cells. |
$1,450,876 |
The American Society of Gene & Cell Therapy |
Eddie Hopkins |
Conference II |
The American Society of Gene & Cell Therapy: 26th Annual Meeting |
$50,000 |
University of California, Irvine |
Mathew Blurton-Jones |
Conference II |
ALSP Community Conference: Insights and Potential of Cell-Based Therapies for the Treatment of Leukodystrophies |
$42,500 |
University of California, Davis |
Joseph Anderson |
Late Stage Preclinical Projects |
Hematopoetic stem cell gene therapy for the treatment of Tay-Sachs disease |
$4,048,253 |
Nammi Therapeutics, Inc. |
David Stover |
Late Stage Preclinical Projects |
IND-Enabling activities for the masked immunocytokine, QXL138AM |
$3,999,113 |
Angiocrine Bioscience, Inc. |
Paul Finnegan |
Clinical Trial Stage Projects |
AB-205-301 Phase 3 Trial and Related Activities to Support Clinical Development of AB-205 |
$15,000,000 |
University of California, San Francisco |
Karin Gaensler |
Late Stage Preclinical Projects |
Development of TriLeukeVax, an Engineered Autologous Leukemia Vaccine for Stimulating Cytolytic Immune Responses to Residual Leukemic Stem Cells |
$6,000,000 |
Stanford University |
Natalia Gomez-Ospina |
Late Stage Preclinical Projects |
Genome Editing of Autologous Hematopoietic Stem Cells to Treat Severe Mucopolysaccharidosis type 1 (Hurler Syndrome) |
$5,444,353 |
Stanford University |
Alice Bertaina |
Clinical Trial Stage Projects |
Sequential same donor αβdepleted-HSCT from an HLA-partially matched donor allowing immunosuppression free kidney transplant |
$11,998,188 |
Tachyon Therapeutics, Inc |
Ivan King |
Clinical Trial Stage Projects |
TACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers |
$7,141,843 |
University of California, San Diego |
Stephanie Cherqui |
Therapeutic Translational Research Projects |
CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia |
$4,846,579 |
University of California, Davis |
William Murphy |
Therapeutic Translational Research Projects |
Overcoming resistance to standard CD19-targeted CAR T using a novel triple antigen targeted vector |
$3,869,061 |
Mahzi Therapeutics |
Allyson Berent |
Therapeutic Translational Research Projects |
Development of a Gene Therapy for the Treatment of Pitt Hopkins Syndrome (PHS) - Translating from Animal Proof of Concept to Support Pre-IND Meeting |
$3,800,760 |
City of Hope, Beckman Research Institute |
Jianhua Yu |
Therapeutic Translational Research Projects |
Specific Targeting Hypoxia Metastatic Breast Tumor with Allogeneic Off-the-Shelf Anti-EGFR CAR NK Cells Expressing an ODD domain of HIF-1α |
$6,036,002 |
Greenstone Biosciences, Inc. |
Paul Pang |
Tool Translational Research Projects |
Cell Villages and Clinical Trial in a Dish with Pooled iPSC-CMs for Drug Discovery |
$1,350,000 |
The Biomedical Engineering Society |
Charity Quick |
Conference II |
2023 BMES-CMBE Annual Meeting: "Cell State Transitions in Health, Disease, and Regeneration” |
$22,000 |
Midwinter Conference of Immunologists |
Christel Uittenbogaart |
Conference II |
61st Midwinter Conference of Immunologists |
$48,566 |
Cedars-Sinai Medical Center |
Wafa Tawackoli |
Conference II |
13th Annual California ALS Research Summit |
$50,000 |
International Society for Stem Cell Research |
Chris Barry |
Conference II |
ISSCR Nucleus Forum 2023 |
$25,000 |
University of California, Los Angeles |
Noah Federman |
Alpha Stem Cell Clinics Network Expansion |
Expansion of the Alpha Stem Cell and Gene Therapy Clinic at UCLA |
$8,000,000 |
University of Southern California |
Thomas Buchanan |
Alpha Stem Cell Clinics Network Expansion |
Alpha Clinic Network Expansion for Cell and Gene Therapies |
$7,999,983 |
University of California, Irvine |
Daniela Bota |
Alpha Stem Cell Clinics Network Expansion |
A hub and spoke community model to equitably deliver regenerative medicine therapies to diverse populations across four California counties |
$8,000,000 |
Calidi Biotherapeutics, Inc. |
Boris Minev |
Late Stage Preclinical Projects |
Allogeneic mesenchymal stem cells loaded with oncolytic virus for cancer treatment |
$3,111,467 |
City of Hope, Beckman Research Institute |
Jana Portnow |
Clinical Trial Stage Projects |
A Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas |
$11,999,984 |
Stanford University |
Matthew Porteus |
Alpha Stem Cell Clinics Network Expansion |
The Stanford Alpha Stem Cell Clinic |
$6,920,810 |
University of California, San Francisco |
Mark Walters |
Alpha Stem Cell Clinics Network Expansion |
University of California, San Francisco (UCSF) Alpha Stem Cell Clinic (ASCC) |
$7,994,347 |
Cedars-Sinai Medical Center |
Michael Lewis |
Alpha Stem Cell Clinics Network Expansion |
A comprehensive stem cell and gene therapy clinic to advance new therapies for a diverse patient population in California |
$7,957,966 |
City of Hope, Beckman Research Institute |
Leo Wang |
Alpha Stem Cell Clinics Network Expansion |
The City of Hope Alpha Clinic: A roadmap for equitable and inclusive access to regenerative medicine therapies for all Californians |
$8,000,000 |
University of California, Davis |
Mehrdad Abedi |
Alpha Stem Cell Clinics Network Expansion |
Alpha Stem Cell Clinic for Northern and Central California |
$7,999,997 |
University of California, San Diego |
Catriona Jamieson |
Alpha Stem Cell Clinics Network Expansion |
UC San Diego Health CIRM Alpha Stem Cell Clinic |
$8,000,000 |
Summit for Stem Cell Foundation |
Melissa King |
Conference II |
Summit Live Continuing Medical Education (CME) Webinar Series: Educating Medical Professionals, Patient Advocates and the Public About Evidence-Based Regenerative Medicine and Stem Cells |
$50,000 |
University of California, Berkeley |
Michael Rape |
Foundation - Discovery Stage Research Projects |
Control of OCT4 abundance and function in human stem cells |
$1,234,023 |
University of California, San Francisco |
Robert Blelloch |
Foundation - Discovery Stage Research Projects |
Development of universal off-the-shelf iPSC derived dendritic cells for use as patient specific anti-tumor vaccine |
$1,391,999 |
University of California, San Diego |
Alexis Komor |
Foundation - Discovery Stage Research Projects |
Development of a stem-cell based approach to interpret global effects of genetic variants contributing to neurodevelopmental disease risk |
$1,518,982 |
University of California, San Diego |
Heidi Cook-Andersen |
Foundation - Discovery Stage Research Projects |
Towards a trophectoderm stem-cell model representing human blastocysts of the highest implantation potential |
$1,584,000 |
Stanford University |
Marius Wernig |
Foundation - Discovery Stage Research Projects |
Developing a microglia replacement therapy |
$1,378,365 |